Standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.

LeWEN BURKT Jenburkt Pharmaceuticals Limited UNICORN, 14th Floor, Dattaji Salvi Marg, Off Veera Desai Road, Andheri West, Mumbai 400 053. Phone: 022-67 603 603 Ref. No. JPL/CS/2336/2026 Date: 06" August, 2026. BSE Ltd. P.J. Towers, Dalal Street, Mumbai - 400 001. Script Code : 524731 Sub.: Outcome of Board Meeting held today, i.e. 06'" August, 2026 - standalone Unaudited Financial Results of the Company for the Quarter ended on 30 June, 2026. Reg.: Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Dear Sir, Kindly note that the Audit Committee have reviewed and the Board of Directors of the Company have approved the standalone unaudited financial results of the Company for the quarter from 1* April, 2026 to 30" June, 2026, during their respective meetings held today, i.e. on 06" August, 2026. The said standalone unaudited financial results for the quarter from 1° April, 2026 to 30" June, 2026, duly signed in the format specified under regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed. Also, enclosed alongwith is the limited audit review report of the auditors of the Company, on the standalone unaudited financial results for the quarter ended on 30" June, 2026. The Board Meeting commenced at 02.30 p.m. (IST) and concluded at 5:40 p.m. (IST) on 06" August, 2026. Kindly take on record the above and acknowledge. | Thanking you, Yours faithfully, *e a ## Science hai toh Hope hai 3% Hope hai toh Health hai 4% Health hai toh Happiness hai 3% = Email: info@jenburkt.com www.jenburkt.com CIN No. L24230MH1985PLC036541 one LdJENBU RKT Jenburkt Pharmaceuticals Limited UNICORN, 14th Floor, Dattaji Salvi Marg, Off Veera Desai Road, Andheri West, Mumbai 400 053. Phone: 022-67 603 603 Statement of Standalone Unaudited Financial Results for the Quarter Ended on 30th June, 2026 (%. in Lacs other than EPS) Particulars Quarter Ended Year Ended 30-06-2026] 31-03-2026] 30-06-2025] 31-03-2026 Unaudited Audited} Unaudited Audited | Revenue from Operations 3551.20 4463.23 3552.68 16874.06 Il Other Income 151.32 434.83 205.71 1029.94 il Total income (I + Il) 3702.52 4898.06 3758.39 17904.00 IV Expenses (a)|Cost of Materials Consumed 231.59 219.35 213.54 899.35 (b)| Purchase of Stock-in-trade 547.84 869.61 537.24 2817.89 (c) Changes in inventories of Finished Goods, Stock-in-tra de and WIP -147.24 -222.68 -99.02 -484.67 (d)}Employee benefit expenses 1302.52 951.53 1172.08 4988.22 (e)}| Finance Costs 13.02 12.92 10.99 46.20 (f )|Depreciation and Amortisation Expense 64.07 80.88 72.25 310.76 (g)j Other expenses 1013.81 1220.52 833.11 4279.25 Total Expenses (IV) 3025.61 3132.13 2740.19 12857.00 Vv Profit before exceptional items and tax (III-IV) 676.91 1765.93 1018.20 5047.00 VI Exceptional items Impact of Labour Codes # 0.00 395.11 0.00 395.11 VI Profit before tax (V-VI) 676.91 1370.82 1018.20 4651.89 Vill Tax Expense (i)| Current Tax 100.00 360.00 200.00 1260.00 (ii) Income Tax for previous years 0.00 4.10 0.00 4.10 (iii)| Deferred Tax -11.65 -78.23 39.02 -85.81 IX Profit/(Loss) after Tax (VII-VIII) 588.56 1084.95 779.18 3473.60 X Other Comprehensive Income A (i)| tems that will not be reclassified to profit or loss 163.76 -347.92 155.19 -171.20 _,. {Income Tax relatiing to Items that will not be reclassifi ed to (i) rofit or loss 13.51 26.51 -17.76 18.30 B (i)| [tems that will be reclassified to profit or loss 0.00 0.00 0.00 0.00 _.JIncome Tax relatiing to Items that will be reclassified to profit (10 or toss 0.00 0.00 0.00 0.00 XI Total Comprehensive Income for the period (IX+X) 738.81 763.54 916.61 3320.70 Paid up Equity Share Capital (F.V. Rs.10/- each) 441.33 441.33 441.33 441.33 XI Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Di luted 13.34 24.58 17.66 78.71 Notes: 1 The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th August, 2026. 2 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable. 3. #The Government of India notified the Revised Labour Codes on November 21, 2025, resulting in an increase of 3395.11 lakhs in gratuity M .pPh,& (Ashish U. Bhuta)}- Place : Mumbai ae Date : 6th August, 2026 Chairman & Managing Director & : i. (DIN No: 00226479) s#@ Science hai toh Hope hai 3% Hope hai toh Health hai £8 Health hai toh Happiness hai 3% x Email: info@jenburkt.com www,jenburkt.com CIN No. L24230MH1985PLC036541 3k D.R.MEHTA & ASSOCIATES (CHARTERED A CCOUNTANTS) H-2, EVEREST BUILDING, 9T! FLOOR, TARDEO CIRCLE, MUMBAI - 400034 TEL: 23513758 / 23520330 FAX: 66607263, 9322508373 Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 To the Board of Directors of Jenburkt Pharmaceuticals Limited We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30" June 2026 (the statement). This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted*in India. Our responsibility is to issue a report on the Statement based on our review, We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India.: This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter. For D.R.Mehta & Associates, Chartered Accountants (Firm Reg. No. 106207W) JOmsiee— Partner Vikram Mehta (Membership No. 047347) * UDIN: 260473¢Ne™ pIPHG6ES| Place: Mumbai Date: 6" August 2026